Skip to main content

Mckesson Corporation

Exchange: NYSESector: HealthcareIndustry: Medical Distribution

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable.

Did you know?

MCK's revenue grew at a 9.0% CAGR over the last 6 years.

Current Price

$814.02

-0.14%

GoodMoat Value

$13906.70

1608.4% undervalued
Profile
Valuation (TTM)
Market Cap$100.47B
P/E23.15
EV$113.91B
P/B
Shares Out123.43M
P/Sales0.25
Revenue$397.96B
EV/EBITDA16.21

Mckesson Corporation (MCK) Financial Statements

GoodMoat Analysis

Based on data as of March 26, 2026

McKesson's financial quality is mixed for a value investor. It generates strong, consistent free cash flow and shows solid revenue growth, but its razor-thin profit margins and lack of reported gross margin data are significant concerns that limit overall quality.

Read full analysis
McKesson's financial health presents a profile of strong cash generation but weak profitability. The company's 11.4% YoY revenue growth is solid and indicates a healthy top-line trajectory. However, the critical quality indicators are mixed. The reported profit margin of 1.1% and operating margin of 1.2% are extremely low, failing to meet the framework's typical thresholds for high-quality businesses, which often seek gross margins above 50% for hardware-centric models and stable, expanding profitability. This raises questions about the business's pricing power and cost structure, especially as gross margin data is unavailable for assessment. On a positive note, free cash flow generation is a clear strength. A FCF yield of 4.8% suggests the company is converting its substantial revenue into cash effectively, a key quality metric. The balance sheet appears leveraged, as indicated by the lack of a reported Debt/Equity ratio, which warrants closer scrutiny for a complete health assessment. For growth, the double-digit revenue increase is favourable, but value investors would need to assess if this growth is durable and driven by competitive advantages rather than mere industry volume. Overall, the financial picture is one of a low-margin, high-volume distributor with efficient cash conversion.

MCK Financial Data

EBITDA$6.55B
Revenue (TTM)$397.96B
Gross Profit (TTM)$14.14B
Gross Margin
Operating Margin1.23%
ROE
ROA5.78%
Debt/Equity
Current Ratio0.90
FCF$5.23B
FCF Yield5.20%
Piotroski F-Score
Rev/Share (TTM)$3224.25
50-Day MA$893.47
200-Day MA$811.78
Shares Outstanding0.12B

MCK Computed Insights

FCF$5.23B
FCF Growth Rate7.02%
EPS Growth (CAGR)50.00%
WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

MCK Financial Statements & Data

Mckesson Corporation (MCK) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Mckesson Corporation's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $397.96B. Gross profit (TTM) is $14.14B. EBITDA is $6.55B. Earnings per share (EPS) is $25.72. The P/E ratio is 23.15. Market capitalization is $100.47B.

Free cash flow (FCF) is $5.23B. FCF growth rate is 7.02%. EPS growth CAGR is 50.00%. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Mckesson Corporation's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.